GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Relief Therapeutics Holding SA (OTCPK:RLFTF) » Definitions » ROE %

Relief Therapeutics Holding (Relief Therapeutics Holding) ROE % : -96.20% (As of Jun. 2023)


View and export this data going back to 1990. Start your Free Trial

What is Relief Therapeutics Holding ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Relief Therapeutics Holding's annualized net income for the quarter that ended in Jun. 2023 was $-125.50 Mil. Relief Therapeutics Holding's average Total Stockholders Equity over the quarter that ended in Jun. 2023 was $130.45 Mil. Therefore, Relief Therapeutics Holding's annualized ROE % for the quarter that ended in Jun. 2023 was -96.20%.

The historical rank and industry rank for Relief Therapeutics Holding's ROE % or its related term are showing as below:

RLFTF' s ROE % Range Over the Past 10 Years
Min: -78.2   Med: -23.59   Max: -0.15
Current: -60.41

During the past 13 years, Relief Therapeutics Holding's highest ROE % was -0.15%. The lowest was -78.20%. And the median was -23.59%.

RLFTF's ROE % is ranked worse than
60.21% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs RLFTF: -60.41

Relief Therapeutics Holding ROE % Historical Data

The historical data trend for Relief Therapeutics Holding's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Relief Therapeutics Holding ROE % Chart

Relief Therapeutics Holding Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.06 -42.17 -19.58 -27.65 -30.87

Relief Therapeutics Holding Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -30.46 -26.04 -30.06 -32.34 -96.20

Competitive Comparison of Relief Therapeutics Holding's ROE %

For the Biotechnology subindustry, Relief Therapeutics Holding's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Relief Therapeutics Holding's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Relief Therapeutics Holding's ROE % distribution charts can be found below:

* The bar in red indicates where Relief Therapeutics Holding's ROE % falls into.



Relief Therapeutics Holding ROE % Calculation

Relief Therapeutics Holding's annualized ROE % for the fiscal year that ended in Dec. 2022 is calculated as

ROE %=Net Income (A: Dec. 2022 )/( (Total Stockholders Equity (A: Dec. 2021 )+Total Stockholders Equity (A: Dec. 2022 ))/ count )
=-54.519/( (197.101+156.094)/ 2 )
=-54.519/176.5975
=-30.87 %

Relief Therapeutics Holding's annualized ROE % for the quarter that ended in Jun. 2023 is calculated as

ROE %=Net Income (Q: Jun. 2023 )/( (Total Stockholders Equity (Q: Dec. 2022 )+Total Stockholders Equity (Q: Jun. 2023 ))/ count )
=-125.498/( (156.094+104.805)/ 2 )
=-125.498/130.4495
=-96.20 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2023) net income data. ROE % is displayed in the 30-year financial page.


Relief Therapeutics Holding  (OTCPK:RLFTF) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-125.498/130.4495
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-125.498 / 6.714)*(6.714 / 171.176)*(171.176 / 130.4495)
=Net Margin %*Asset Turnover*Equity Multiplier
=-1869.2 %*0.0392*1.3122
=ROA %*Equity Multiplier
=-73.27 %*1.3122
=-96.20 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2023 )
=Net Income/Total Stockholders Equity
=-125.498/130.4495
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-125.498 / -142.474) * (-142.474 / -25.668) * (-25.668 / 6.714) * (6.714 / 171.176) * (171.176 / 130.4495)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8808 * 5.5506 * -382.31 % * 0.0392 * 1.3122
=-96.20 %

Note: The net income data used here is two times the semi-annual (Jun. 2023) net income data. The Revenue data used here is two times the semi-annual (Jun. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Relief Therapeutics Holding ROE % Related Terms

Thank you for viewing the detailed overview of Relief Therapeutics Holding's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Relief Therapeutics Holding (Relief Therapeutics Holding) Business Description

Traded in Other Exchanges
Address
Avenue de Secheron 15, Fondation EIP, Batiment, Geneva, CHE, CH-1202
Relief Therapeutics Holding SA is engaged in the research, development, and commercialization of biopharmaceutical products. It mainly develops drugs of natural human origin. It has a focus on commercial products and the development program pipeline is focused on three main areas: rare genetic, metabolic disorders, rare connective tissue disorders, and rare lung diseases. Geographically group generates the majority of its revenue from Europe.

Relief Therapeutics Holding (Relief Therapeutics Holding) Headlines

From GuruFocus

Relief Therapeutics to Participate in January Investor Meetings

By ACCESSWIRE ACCESSWIRE 12-14-2022

Relief Therapeutics Announces Executive Leadership Team Changes

By ACCESSWIRE ACCESSWIRE 12-08-2022